-
Controversial Alzheimer’s Drug Aduhelm Dropped by Drugmaker After Doubtful Data and Denied Coverage -
Many Ineligible for New Alzheimer’s Drugs: Study
-
FDA’s Approval Process of Controversial Alzheimer’s Drug Was ‘Rife With Irregularities’: Congressional Probe
-
Biden Touts Reduction of 2023 Medicare Fees, Due Largely to Limiting of Alzheimer’s Drug
-
FDA Finally Approved an Alzheimer’s Drug—But Everything Surrounding It Is Controversial
-
Fixed Packaging of Alzheimer’s Drug May Waste $605 Million a Year for Medicare, Experts Warn
-
Biogen CEO to Step Down, Drugmaker Pulls Back on Alzheimer’s Drug Aduhelm
-
Medicare Officially Limits Coverage of Alzheimer’s Drug to Those in Clinical Trials
-
Biden Administration Decides to Limit Medicare Coverage of New Alzheimer’s Drug
-
CMS May Review Medicare Premium in Light of Aduhelm Price Drop
-
Biogen Halves Price of Alzheimer’s Drug to $28,200
